Variable (n = 13) | N (%) |
---|---|
Performance status (1 st line) | |
0 | 1 (7.7%) |
1 | 12 (92.3%) |
Menopausal status | |
Premenopausal | 1 (7.7%) |
Postmenopausal | 12 (92.3%) |
Number of comorbidities | |
0–1 | 11 (84.6%) |
2–3 | 2 (15.4%) |
Initial management at diagnosis | |
Surgical resection alone | 5 (38.5%) |
Surgical resection and BSO | 8 (61.5%) |
Prior exogenous estrogens | |
Tamoxifen | 3 (23%) |
HRT | 7 (53.8%) |
Prior pelvic radiotherapy | 4 (30.8%) |
Sites of metastases at time of 1 st line | |
Pelvic | 6 (46.2%) |
Extrapelvic | 3 (23%) |
Both pelvic and extrapelvic disease | 4 (30.8%) |
Tumour volume at 1 st line | |
Low | 1 (7.7%) |
High | 12 (92.3%) |
Number of metastases at 1 st line | |
Oligometastatic | 5 (38.5%) |
Multiple | 8 (61.5%) |
Hormone receptor status | |
ER | |
Moderate to strong (grade 2–3) | 9 (69.2%) |
Weak (grade 1) | 0 (7.1%) |
NA | 4 (30.8%) |
PgR | |
Moderate to strong (grade 2–3) | 9 (69.2%) |
Weak (grade 1) | 0 (7.1%) |
NA | 4 (30.8%) |